M.S., mechanical and aerospace engineering, University of Virginia; Engineer with Highest Distinction, Moscow State Technical University
Summary of Experience:
Mr. Yermakov has more than 10 years of consulting experience in business strategy and economics of life sciences industries.
His strategy work covers the spectrum of issues that clients face, from assessing new markets and business opportunities to managing product life cycles. Among his many strategy engagements, Mr. Yermakov has helped a large player in virology evaluate new market opportunities and in-licensing targets; advised senior management of a leading medical products company on growth strategies for a $3 billion cardiovascular franchise comprising pharmaceutical, vascular device, and diagnostic units; and advised a joint development committee of a U.S.–French partnership on life-cycle management options for its $1 billion drug.
Mr. Yermakov has also led teams conducting a wide range of complex economic analyses for clients in the life sciences industries. His recent engagements have included assessing the impact of marketing and clinical strategies on sales of a monoclonal antibody in oncology; conducting pharmacoeconomic analyses of the value of antipsychotic drugs; and developing models to analyze profits by payer and indication for novel biologic therapies. Prior to joining Analysis Group, Mr. Yermakov was with Credit Suisse First Boston in New York.